Blog

OEVEL, Belgium–(BUSINESS WIRE)–
The Estée Lauder Companies Inc. (NYSE:EL), today celebrated the sixtieth anniversary of its Manufacturing & Fulfillment Campus in Oevel, Belgium. Since its opening in 1965, the Oevel Campus has developed into a state-of-the-art manufacturing, fulfillment and biotech hub. Today the campus serves as a cornerstone of the company’s global value chain and is one of its largest manufacturing facilities by volume, annually producing over 100 million prestige beauty products, which are then shipped to more than 100 countries.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016330616/en/

“Nearly sixty years ago, my grandparents, Estée and Joseph Lauder, laid the cornerstone of our first facility here in Oevel, establishing what would become a vital part of our global operations,” said William P. Lauder, Chair, Board of Directors, The Estée Lauder Companies. “From those early days, our Oevel Campus has evolved into a vibrant community and one of our most advanced centers for manufacturing and innovation. It reflects and embodies the visionary spirit of my grandmother, Mrs. Estée Lauder, as well as who we are as a company. This anniversary is both a celebration of our people and a tribute to the enduring partnerships that have shaped The Estée Lauder Companies’ legacy in Europe.”

The celebration brought together hundreds of the Oevel Campus employees, Belgian government officials, media, and leadership from across The Estée Lauder Companies for a day of reflection and recognition. Guests explored a heritage exhibit, toured the manufacturing plant, and unveiled a commemorative sixtieth-anniversary mural.

“The evolution of our Oevel Campus is a powerful reflection of how The Estée Lauder Companies honors its heritage while moving boldly into the future,” said Stéphane de La Faverie, President and Chief Executive Officer. “As one of our most advanced and sustainable manufacturing sites, our campus here exemplifies how we are reimagining beauty through innovation, quality, and responsibility – driven every day by the passion and expertise of our people.”

“The Estée Lauder Companies’ site in Belgium has become a global benchmark in innovation, sustainability and beauty,” said Matthias van Diepenaele, President of Flanders. “Flanders is proud of this long-term partnership, which creates economic added value, but also demonstrates confidence in our people, our expertise and our future. Many congratulations to the company, its employees and the Lauder family.”

The Oevel Campus’s transformation over six decades reflects The Estée Lauder Companies’ strategic investments in technology, sustainability, and talent. Today, the campus spans more than 100,000 square meters across multiple buildings, having grown fivefold from its original footprint. The site now includes a cutting-edge BioTech Hub in nearby Olen, where scientists produce bio-based raw materials using fermentation and biotechnology, advancing The Estée Lauder Companies’ commitment to sustainability and innovation. The Oevel Campus has evolved from the original ‘Lauder Blue Plant’ – inspired by the packaging used at the time – into a future-ready campus that supports more than twenty brands. The facility enables rapid new product launches and personalized manufacturing, with advanced technologies and AI integrated throughout.

As part of The Estée Lauder Companies’ value chain regionalization strategy, approximately 70% of products sold in Europe are produced within the region, reducing long-haul transport needs and supporting local economies. The Oevel Campus’s growth and transformation exemplify ELC’s focus on operational excellence, transformative innovation, and its enduring commitment to Belgium and Europe.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include those in the various quotations. Although the Company believes that its expectations are based on reasonable assumptions within the bounds of its knowledge of its business and operations, actual results may differ materially from the Company’s expectations. Factors that could cause actual results to differ from expectations include the ability to successfully implement the Company’s strategy, including Beauty Reimagined and the profit recovery and growth plan; successfully transition its leadership; and those other factors described in the Company’s filings with the Securities and Exchange Commission, including its most recent filings with the Securities and Exchange Commission. The Company assumes no responsibility to update forward-looking statements made herein or otherwise.

About The Estée Lauder Companies

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, the DECIEM family of brands, including The Ordinary and NIOD, and BALMAIN Beauty.

ELC-C

View source version on businesswire.com: https://www.businesswire.com/news/home/20251016330616/en/

Media Relations:

Maud Smith

[email protected]

Investor Relations:

Rainey Mancini

[email protected]

Source: The Estée Lauder Companies Inc.

• Warburg Pincus enters exclusive negotiations to acquire a significant minority stake in Sebia
• Existing shareholders CVC Funds, La Caisse (formerly CDPQ) and Téthys Invest to remain significant investors

Sebia, a global leader in specialty diagnostics, and Warburg Pincus, the pioneer of private equity global growth investing, today announced that Warburg Pincus has entered into exclusive negotiations for the potential acquisition of a significant minority stake in Sebia.  

Sebia is a global specialized In Vitro Diagnostics player providing equipment and reagents for the screening and monitoring of various diseases, primarily in the areas of Oncology (Multiple Myeloma), Diabetes, Hemoglobinopathy, Autoimmune and Infectious diseases and other rare pathologies. The company serves customers in more than 140 countries through a broad installed base and a portfolio of proprietary reagents and instruments.

Jean-Marc Chermette, Chief Executive Officer of Sebia, said: “Our mission is to provide powerful tools that translate what is happening in a patient’s body into a readable and interpretable language. We welcome Warburg Pincus as a new partner alongside our existing investor base. Their global healthcare expertise and growth orientation will help accelerate Sebia’s strategy while maintaining our commitment to scientific rigor, product quality and patient impact, helping us deliver for our customers and partners.”

TJ Carella, Managing Director and Global Head of Healthcare, and Jake Strauss, Managing Director and Head of European Healthcare at Warburg Pincus, said: “Sebia is a best-in-class diagnostics platform with differentiated technology and a strong track record of delivering innovative products and solutions to customers and patients worldwide. We are excited to partner with Jean-Marc, the management team, and existing shareholders to support the company’s next phase of growth, including continued advances in diagnostic modalities, scientific excellence and manufacturing capabilities.”

The terms of the proposed transaction are not disclosed. Following completion, Sebia will continue to operate as an independent company from its headquarters in Lisses, France.

Execution of the proposed transaction remains subject to completion of applicable employee consultation processes, and receipt of customary regulatory approvals. Closing is expected to occur no earlier than Q1 2026.